Submitted by dcc on Tue, 2020-01-21 09:58 Study Title: A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid LeukemiaCIRB: Pediatric CIRBLead Group: PEP-CTNStatus: ActiveReview Status: Available to Open
